Acorda Therapeutics
Acorda Therapeutics Announces Availability of AMPYRA(TM) dalfampridine
Published in MD Week, March 19th, 2010
Acorda Therapeutics, Inc. (Nasdaq: ACOR) announced that AMPYRA™ (dalfampridine) Extended Release Tablets, 10 mg is now available by prescription in the United States and Puerto Rico. AMPYRA was approved on January 22, 2010 by the U.S. Food and Drug Administration (FDA) as a treatment to improve walking in patients with multiple sclerosis (MS). This was demonstrated by an increase in walking speed. AMPYRA is indicated for use in all types of MS, and can be used either alone or with existing therapies, including disease-modifying agents.
"The majority of people with MS experience a decline in their walking as their disease progresses. The availability of AMPYRA...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of MD Week
Source: MD Week (2010-03-19)
More Articles from MD Week
- Alzheimer's Association
Negative Phase III Trial Results for Latrepirdine Dimebon - American BioSciences Inc.
'Less Is More' with the Innovation of Avemar Fermented Wheat Germ Extract - American College of Radiology
President Obama Gets Virtual Colonoscopy CT Colonography but Medicare Denies CTC Coverage to Seniors - American HomePatient, Inc.
American HomePatient Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2009 - American Physical Therapy Association
APTA Joins with Patient and Health Care Groups on Capitol Hill in Calling for Long-Term Solution to Therapy Cap - American Public Health Association
Nation's Public Health Associations Call on Congress to Pass Health Reform - More from this issue of MD Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
